- Home
- OLMA vs TECX Comparison
OLMA vs TECX Comparison
Compare OLMA & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- TECX
- Stock Information
- Founded
- OLMA 2006
- TECX 2019
- Country
- OLMA United States
- TECX United States
- Employees
- OLMA N/A
- TECX N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- TECX
- Sector
- OLMA Health Care
- TECX
- Exchange
- OLMA Nasdaq
- TECX Nasdaq
- Market Cap
- OLMA 289.0M
- TECX 334.4M
- IPO Year
- OLMA 2020
- TECX 2018
- Fundamental
- Price
- OLMA $5.28
- TECX $21.51
- Analyst Decision
- OLMA Strong Buy
- TECX Buy
- Analyst Count
- OLMA 4
- TECX 6
- Target Price
- OLMA $24.50
- TECX $79.20
- AVG Volume (30 Days)
- OLMA 688.0K
- TECX 172.8K
- Earning Date
- OLMA 05-13-2025
- TECX 05-08-2025
- Dividend Yield
- OLMA N/A
- TECX N/A
- EPS Growth
- OLMA N/A
- TECX N/A
- EPS
- OLMA N/A
- TECX N/A
- Revenue
- OLMA N/A
- TECX N/A
- Revenue This Year
- OLMA N/A
- TECX N/A
- Revenue Next Year
- OLMA N/A
- TECX N/A
- P/E Ratio
- OLMA N/A
- TECX N/A
- Revenue Growth
- OLMA N/A
- TECX N/A
- 52 Week Low
- OLMA $2.86
- TECX $13.70
- 52 Week High
- OLMA $16.62
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- OLMA 60.00
- TECX 51.42
- Support Level
- OLMA $4.80
- TECX $21.20
- Resistance Level
- OLMA $5.61
- TECX $22.75
- Average True Range (ATR)
- OLMA 0.38
- TECX 1.43
- MACD
- OLMA 0.02
- TECX 0.01
- Stochastic Oscillator
- OLMA 78.71
- TECX 41.32
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.